Stockscreener 앱 받기
20.08
2.50%
0.49
시간 외 거래:
20.08
전일 마감가:
$19.59
열려 있는:
$20.32
하루 거래량:
177.96K
Relative Volume:
0.54
시가총액:
$692.31M
수익:
$4.12M
순이익/손실:
$-56.68M
주가수익비율:
-3.6227
EPS:
-5.5429
순현금흐름:
$-51.44M
1주 성능:
-6.82%
1개월 성능:
+14.03%
6개월 성능:
-27.46%
1년 성능:
-17.33%
1일 변동 폭
$19.69
$21.44
1주일 범위
$19.35
$21.56
52주 변동 폭
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
929-999-4055
주소
7 TIMES SQUARE, NEW YORK
DNTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
20.08 | 692.31M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results - The Manila Times
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Lifted by Braidwell LP - MarketBeat
Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - MSN
106,434 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Bought by Ally Bridge Group NY LLC - MarketBeat
5AM Venture Management LLC Sells 203,908 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Wells Fargo & Company MN Sells 8,271 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Allostery Investments LP Buys New Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $54.33 - MarketBeat
Barclays PLC Raises Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
180,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Adage Capital Partners GP L.L.C. - MarketBeat
Dianthus Therapeutics completes enrollment for MaGic trial - Investing.com Australia
Dianthus Therapeutics completes enrollment for MaGic trial By Investing.com - Investing.com Canada
Dianthus (DNTH) Completes Enrollment for Phase 2 MaGic Trial | D - GuruFocus
Dianthus Therapeutics Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
Breakthrough gMG Treatment DNTH103 Hits Major Milestone: Phase 2 Results Coming This Fall - Stock Titan
Invesco Ltd. Purchases 790 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
TCG Crossover Management LLC Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
JPMorgan Chase & Co. Increases Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownHere's What Happened - MarketBeat
Legal & General Group Plc Buys 2,363 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
BlackRock, Inc. Reduces Stake in Dianthus Therapeutics Inc. - GuruFocus
Dianthus Therapeutics to Participate in Two Upcoming Investor Events - The Manila Times
Dianthus Therapeutics Reveals Growth Strategy at Two Elite Healthcare Investment Forums - Stock Titan
Dianthus Therapeutics (DNTH) Sees Rise in Short Interest Despite Stock Rebound | DNTH Stock News - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4%Time to Buy? - MarketBeat
Bain Capital Life Sciences Investors LLC Sells 323,716 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Walleye Capital LLC Purchases 52,890 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead - Seeking Alpha
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Geode Capital Management LLC - Defense World
Fmr LLC Purchases 36,133 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Vanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
A stock that deserves closer examination: Dianthus Therapeutics Inc (DNTH) - uspostnews.com
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.10%
자본화:
|
볼륨(24시간):